EUCTR2015-002353-35-IT进行中（未招募）1 期
A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (EXPEDITION-4 - N.A.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 104
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female at least 18 years of age at time of Screening.
- •2. Screening laboratory result indicating chronic HCV GT1-6 infection.
- •3. Subject must be HCV treatment-naïve or have received prior HCV treatment with IFN or pegIFN with or without RBV, pegIFN/RBV plus SOF, or SOF plus RBV.
- •4. Subject must have chronic renal impairment (CKD stage 4 or 5).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. History of severe, life-threatening or other significant sensitivity to any excipients of the study drug.
- •2. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.
- •3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.
- •4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).
- •5. HCV genotype performed during screening indicating co-infection with more than one HCV genotype.
研究者
相似试验
进行中（未招募）
1 期
A Study to evaluate the Effect and Safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Renal ImpairmentChronic HCV Genotype 1-6 InfectionMedDRA version: 19.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2015-002353-35-GBAbbVie Deutschland GmbH & Co. KG104
进行中（未招募）
1 期
A Study to evaluate the Effect and Safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Renal ImpairmentChronic HCV Genotype 1-6 InfectionMedDRA version: 18.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-002353-35-BEAbbVie Deutschland GmbH & Co. KG100
进行中（未招募）
1 期
A Study to evaluate the Effect and Safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Renal ImpairmentChronic HCV Genotype 1-6 InfectionMedDRA version: 18.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-002353-35-GRAbbVie Deutschland GmbH & Co. KG100
招募中
2 期
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitislcerative ColitisJPRN-jRCT2031230586Kawai Norisuke36
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-ITF. HOFFMANN - LA ROCHE LTD.600